Home/ Stocks/ CGON

CG Oncology, Inc. Common stock

CGON XNAS

$69.62 +0.44 (+0.64%) ▲ 15-min delayed

Open

$68.90

High

$70.31

Low

$68.55

Volume

1.14M

Market Cap

$6.13B

About CG Oncology, Inc. Common stock

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 142 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$4.04M	$-160,995,000	$-2.08
FY 2025	$4.04M	$-160,995,000	$-2.08
Q3 2025	$1.67M	$-43,808,000	$-0.57
Q2 2025	$-0	$-41,426,000	$-0.54

Earnings & Analyst Ratings

Next Earnings: Thu, Aug 6, 2026

Calendar →

Related Market News

No specific coverage for CGON yet. Check out our latest market news or earnings calendar.

Get CGON Alerts

Stay ahead with breaking news, price alerts, and expert analysis on CG Oncology, Inc. Common stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.